Role of p53 in the induction of cyclooxygenase-2 by cisplatin or paclitaxel in non-small cell lung cancer cell lines
Authors:
- Mariana Lemos DuarteMDMariana Lemos Duarte
- Emanuela de MoraesEMEmanuela de Moraes
- Luciene SchluckebierLSLuciene Schluckebier
- Pierre HainautPHPierre Hainaut
- Carlos Gil FerreiraCFCarlos Gil Ferreira
- 1 June 2009
- journal article
- Published by Elsevier in Cancer Letters
- Vol. 279 (1) , 57-64
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Cyclooxygenase 2-Dependent Expression of Survivin Is Critical for Apoptosis Resistance in Non-Small Cell Lung CancerCancer Research, 2004
- Multifaceted roles of cyclooxygenase-2 in lung cancerDrug Resistance Updates, 2004
- Lung cancer and cyclooxygenase-2The Annals of Thoracic Surgery, 2003
- Signal Transduction Pathways of Taxanes-Induced ApoptosisCurrent Medicinal Chemistry - Anti-Cancer Agents, 2003
- Molecular approaches to lung cancer evaluationLung Cancer, 2002
- Prognostic Significance of Cyclooxygenase 2 mRNA Expression in Non-Small Cell Lung CancerAnnals of Surgery, 2002
- Cyclooxygenase-2: a novel target for cancer chemotherapy?Journal of Cancer Research and Clinical Oncology, 2001
- Increased cyclooxygenase 2 (COX-2) expression occurs frequently in precursor lesions of human adenocarcinoma of the lungLung Cancer, 2000
- Cyclooxygenase‐2 (COX‐2) mRNA Expression Levels in Normal Lung Tissues and Non‐small Cell Lung CancersJapanese Journal of Cancer Research, 1999
- A common pharmacophore for cytotoxic natural products that stabilize microtubulesProceedings of the National Academy of Sciences, 1999